Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Med Princ Pract ; 21(6): 543-7, 2012.
Article in English | MEDLINE | ID: mdl-22722224

ABSTRACT

OBJECTIVE: To assess the susceptibility trends of community-acquired extended-spectrum ß-Iactamase (ESBL)-producing urinary isolates with particular reference to fosfomycin, nitrofurantoin and tigecycline. MATERIALS AND METHODS: Seven hospitals across the United Arab Emirates participated in this study from June 2008 to March 2010. The antibiotic sensitivity of ESBL-producing uropathogens to a panel of antibiotics including tigecycline, fosfomycin and nitrofurantoin was assessed. The Hyplex ESBL identification system (h-ES-ID) was used for genotypic identification. RESULTS: Two hundred and ninety-two ESBL-producing Enterobacteriaceae isolates were identified during the study period. Of these, 182 (62%) were urinary isolates and comprised of Escherichia coli: 149 (81.9%), Klebsiella pneumoniae: 30 (16.5%) and Proteus mirabilis: 3 (1.6%). Of the 182 urinary isolates, 179 (98.3%) were from patients with community onset urinary tract infections. The h-ES-ID system identified 172 (94.5%) of the urinary isolates as CTX-M positive. All isolates were susceptible to imipenem and meropenem. Over half of the isolates showed resistance to gentamicin (98; 53.8%), trimethoprim-sulfamethoxazole (139; 76.4%) and ciprofloxacin (143; 78.6%). Sensitivity to nitrofurantoin and fosfomycin was 90 and 100%, respectively. Two CTX-M-positive K. pneumoniae isolates with tigecycline resistance (MIC >4 µg/ml) were identified. CONCLUSION: There is dissemination of CTX-M ESBL-producing urinary pathogens into the community. Fosfomycin and nitrofurantoin were active against ESBL-positive uropathogens, and emergence of tigecycline resistance needs close monitoring.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Urinary/therapeutic use , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/drug effects , Urinary Tract Infections/microbiology , beta-Lactam Resistance , Anti-Bacterial Agents/pharmacology , Chi-Square Distribution , Enterobacteriaceae Infections/genetics , Fosfomycin/pharmacology , Fosfomycin/therapeutic use , Genotype , Humans , Minocycline/analogs & derivatives , Minocycline/pharmacology , Minocycline/therapeutic use , Nitrofurantoin/pharmacology , Nitrofurantoin/therapeutic use , Tigecycline , United Arab Emirates , Urinary Tract Infections/drug therapy , Urinary Tract Infections/genetics
SELECTION OF CITATIONS
SEARCH DETAIL